TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03697538

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve Block for pain control post-revision total knee arthroplasty
Description: A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block for pain control post-revision total knee arthroplasty
Description: A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
Study: NCT03666403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIV rate: 0/min
Description: A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIV rate: 10-20/min
Description: A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIV rate: 5-10/min
Description: A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
Study: NCT01340417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements of melatonin levels in urine, blood, milk.
Description: Measurements of melatonin levels in urine, blood, milk.
Study: NCT01352611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baclofen, intrathecal
Description: Patients will undergo a standard intrathecal baclofen trial procedure. This procedure consists of a single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
Study: NCT04603417

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electroencephalography (EEG)/Magnetoencephalography (MEG)/MRI
Description: This cross-sectional study will present the participants with an instrumental pain avoidance learning task, while we record continuous Magnetoencephalography (MEG) brain signals, and other autonomic measurements. All patients will complete behavioral, neuropsychological and pain assessments to rate their current pain, disability, fear, anxiety, and depression using standardized scales.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electroencephalography (EEG)/Magnetoencephalography (MEG)/MRI
Description: This cross-sectional study will present the participants with an instrumental pain avoidance learning task, while we record continuous Magnetoencephalography (MEG) brain signals, and other autonomic measurements. All patients will complete behavioral, neuropsychological and pain assessments to rate their current pain, disability, fear, anxiety, and depression using standardized scales.
Study: NCT04441645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: acupressure once per day, five times per week, a total of 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: acupressure once per day, five times per week, a total of 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: acupressure once per day, five times per week, a total of 12 weeks
Study: NCT03617627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Description: Self-management intervention will include presentation and discussion of various topics regarding chronic pain mechanisms and pain self-monitoring. The intervention will also incorporate a task-oriented approach focused on relevant activities in order to acquire coping skills.
Study: NCT04121117

Intervention type: OTHER
Intervention: Chronic obstructive pulmonary disease screening
Description: To verify the tobacco withdrawal, the patients will make a cooximetry.~For the detection of a possible obstructive pattern a measurement of the ventilatory capacity will be make using the COPD-6 device and for the confirmation of COPD diagnosis and the assesment of the airflow obstruction severity a spirometry will be make.~The patients will also complete the COPD-PS questionnaire.
Study: NCT02039752

Intervention type: OTHER
Intervention: Treatment
Study: NCT01037582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN9924 (oral)
Description: Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN9924 (oral)
Description: Subjects will be randomized to receive a single dose of NN9924 in one of three different concentrations. The dose will be selected based on the results of part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will be randomized to receive a single dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN9924 (s.c.)
Description: As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN9924 (i.v.)
Description: As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.
Study: NCT00802282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin
Description: dose manipulation as described in the protocol and to which volunteers are blinded

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin
Description: dose manipulation as described in the protocol and to which volunteers are blinded

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin
Description: dose manipulation as described in the protocol and to which volunteers are blinded

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin
Description: dose manipulation as described in the protocol and to which volunteers are blinded

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin
Description: dose manipulation as described in the protocol and to which volunteers are blinded

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity of support for spiritual practice
Description: Volunteers will be assigned to standard or high support, as described in the protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity of support for spiritual practice
Description: Volunteers will be assigned to standard or high support, as described in the protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity of support for spiritual practice
Description: Volunteers will be assigned to standard or high support, as described in the protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity of support for spiritual practice
Description: Volunteers will be assigned to standard or high support, as described in the protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity of support for spiritual practice
Description: Volunteers will be assigned to standard or high support, as described in the protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Number of sessions
Description: Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Number of sessions
Description: Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Number of sessions
Description: Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Number of sessions
Description: Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Number of sessions
Description: Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol
Study: NCT01793818

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tat Oyi
Description: Three injections in the arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tat Oyi
Description: Three injections in the arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tat Oyi
Description: Three injections in the arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tat Oyi
Description: Three injections in the arm
Study: NCT01991288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNB Saphenous Nerve Block
Description: Patients in group SNB received an ultrasound guided SNB (a sub sartorial approach) by a single operator with 10 mls 0.5% bupivacaine. At the end of surgery periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline was performed in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NSNB Non Saphenous Nerve Block
Description: All patients at the end of surgery received periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline, in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
Study: NCT00799916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation (Voluven)
Description: Resuscitation aimed at venous oxygen saturation higher than 70%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation (Saline)
Description: Resuscitation aimed at venous oxygen saturation higher than 70%
Study: NCT01355354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: oral tablets, 0.25mg bd on Day 1 and 0.25 Once daily from Day 2 to 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: oral tablets, 0.25mg bd on Day 1 and 0.25 Once daily from Day 2 to 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: oral tablets, 100mg (2 X 50mg) bd from Day 9 - 15
Study: NCT01932099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Description: Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.
Study: NCT04600024

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound guided diagnostic injection
Description: 4 cc lidocaine %2 injection into the piriformis muscle was performed for the diagnosis of piriformis syndrome. It was performed by the ultrasound-guidance to increase the accuracy of the injection.
Study: NCT00685802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 50 mg Tablets
Description: Cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol (Pletal®) 50 mg Tablets
Description: Cilostazol (Pletal® Tablets, 2 x 50mg) administered after an overnight fast of at least 10 hours.
Study: NCT01443559

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Xenogenic cornea
Description: lamellar acellular xenogenic corneas were sterilised by radiation

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: homogenic cornea
Description: homogenic corneas were sterilised by radiation
Study: NCT02332408

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cybernetic microradiosurgery
Description: Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy
Description: Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)
Study: NCT00751738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azimilide dihydrochloride
Description: oral, once daily until sponsor stopped the study
Study: NCT03458247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate standard dose
Description: 1000 mg/day
Study: NCT03505983

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESR Prosthetic Foot First
Description: Subjects will start with an ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
Study: NCT03609879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NECKLITE
Description: patient with a fitted cervical collar (NECKLITE) established by an experienced instructor. Cervical collar set up for 20 minutes
Study: NCT02147470

Intervention type: DRUG
Group type: OTHER
Intervention: Definity ultrasound contrast agent
Description: All subjects will undergo CEUS of the kidney at baseline to measure renal blood flow. This procedure will be repeated after volume expansion and if indicated, once again after treatment with albumin, midodrine and octreotide.
Study: NCT00129272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion-SR
Description: 150mg tablets taken orally twice daily for 9 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (to Buproion-SR) twice daily for 9 weeks.
Study: NCT03505983

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Articulating ESR Prosthetic Foot First
Description: Subjects will start with an articulating ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Powered Prosthetic Foot First
Description: Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR foot and an ESR foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
Study: NCT03611712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus Polysaccharides 500 mg
Description: PG2 Lyo. Injection 500 mg will be given on 1 week before CCRT (Week 1, PG2 Lyo. Injection 500 mg, b.i.w), during CCRT (Week 2-6, PG2 Lyo. Injection 500 mg, t.i.w for 5 weeks), and after CCRT (Week 7-8, PG2 Lyo. Injection 500 mg, t.i.w for 2 weeks)
Study: NCT03358693

Intervention type: DRUG
Intervention: Ustekinumab
Description: Subject receives Ustekinumab open-label as per guidelines

Intervention type: DRUG
Intervention: Infliximab
Description: Subject receives Infliximab open-label as per guidelines

Intervention type: DRUG
Intervention: Secukinumab
Description: Subject receives Secukinumab open-label as per guidelines

Intervention type: DRUG
Intervention: Dupilumab
Description: Subject receives Dupilumab open-label as per guidelines

Intervention type: DRUG
Intervention: Brodalumab
Description: Subject receives Brodalumab open-label as per guidelines

Intervention type: DRUG
Intervention: Ixekizumab
Description: Subject receives Ixekizumab open-label as per guidelines

Intervention type: DRUG
Intervention: Baricitinib
Description: Subject receives Baricitinib open-label as per guidelines

Intervention type: DRUG
Intervention: Abrocitinib
Description: Subject receives Abrocitinib open-label as per guidelines

Intervention type: DRUG
Intervention: Upadacitinib
Description: Subject receives Upadacitinib open-label as per guidelines

Intervention type: DRUG
Intervention: Tralokinumab
Description: Subject receives Tralokinumab open-label as per guidelines
Study: NCT04826198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AsiDNA
Description: Unit dose: Vial containing 100 mg of AsiDNA™ (free acid) Regimen: 3 consecutive infusions (D1, D2, D3) followed by a once a week iv infusion on D8 and D15 of a 21 day-treatment cycle at first cycle, then weekly iv infusion in the absence of disease progression or unacceptable toxicity Mode/route: 1 hour intravenous (iv) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Unit dose: Hard capsule containing 100mg of Niraparib Regimen: The last dose given during the 6 previous months of Niraparib 200 mg/day or 300 mg/day, (or 100 mg/day only if the patient has received this dose since at least 6 months) Daily, 1, 2 or 3 hard capsules at 100mg once daily at approximately the same time each day.~Mode/route: Per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Product name: Olaparib Pharmaceutical form: Tablets containing 100 or 150mg of Olaparib Route of administration: per os Dose Regimen: The last dose given during the 6 previous months of Olaparib 600 mg/day or 500 mg/day, (or 400 mg/day only if the patient has received this dose since at least 6 months) Two times daily (300mg or 250 mg or 200mg) at approximately the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Product name: Rucaparib Pharmaceutical form: Tablets containing 200 or 250 or 300mg of Rucaparib Route of administration: per os Dose Regimen: The last dose given during the 6 previous months of Rucaparib 1200 mg/day or 1000 mg/day, or 800mg/day (or 600 mg/day only if the patient has received this dose since at least 6 months) Two times daily (600mg or 500mg or 400mg or 300mg) at approximately the same time each day.
Study: NCT06560944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill
Description: Ingesting their existing combined oral contraceptive pill at a specific time of day in relation to assessment of outcome measures

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combined oral contraceptive pill
Description: Ingesting their existing combined oral contraceptive pill at a specific time of day in relation to assessment of outcome measures
Study: NCT04101344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two fiber-blend snack and four fiber-blend snack
Description: All subjects will complete a 47-day, multi-phase feeding study to evaluate the effect of two snack prototypes containing two different fiber blends on gut community structure and features of host biological state (plasma proteome/ metabolome).
Study: NCT04224701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted
Description: 30 µg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted
Description: 300 µg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris NaCl Diluent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris NaCl Diluent
Study: NCT04332783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychophysics of sequential biases (no drug or patient work)
Description: Psychophysical experiment on sequential effects in medical image perception. Observers, including clinicians, perform psychophysical continuous report match-to-sample and forced-choice discrimination judgments of medical images, including radiographs and photographs. Observer discrimination accuracy is measured on a trial-wise basis and sequential effects in those judgments are measured. Images can be presented with different interstimulus intervals and in different spatial locations and in different orders. Accuracy, and other signal detection metrics are computed as a function of these factors.
Study: NCT03769350

Intervention type: DEVICE
Group type: OTHER
Intervention: Smartphone-delivered CBT for MDD
Description: 8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
Study: NCT00776204

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JACTAX Drug eluting stent
Description: Jactax stent placed in coronary artery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JACTAX LD drug eluting stent
Description: JACTAX LD stent placed in coronary artery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Libertè
Description: Taxus Libertè stent placed in coronary artery